DiaMedica Therapeutics(DMAC) - 2025 Q1 - Quarterly Results

Financial Performance - Net loss for Q1 2025 was $7.7 million, or $0.18 loss per share, compared to a net loss of $5.2 million, or $0.14 loss per share, in Q1 2024[8] - For the three months ended March 31, 2025, the net loss was $7,707,000, compared to a net loss of $5,151,000 for the same period in 2024, representing a 49% increase in net loss year-over-year[19] - The company reported a basic and diluted net loss per share of $0.18 for Q1 2025, compared to $0.14 for Q1 2024, reflecting a 29% increase in loss per share[19] Cash and Investments - Cash, cash equivalents, and short-term investments were $37.3 million as of March 31, 2025, down from $44.1 million as of December 31, 2024[8] - The company anticipates its current cash position will fund planned clinical studies and support operations into Q3 2026[8] - Cash and cash equivalents at the end of the period were $2,589,000, down from $3,025,000 at the beginning of the period, a decrease of 14%[23] - The company experienced a net cash provided by investing activities of $6,622,000 in Q1 2025, compared to $4,208,000 in Q1 2024, an increase of 57%[23] Operating Activities - Net cash used in operating activities for Q1 2025 was $7.1 million, compared to $6.7 million for the same period in 2024, reflecting an increase in net loss[8] - Net cash used in operating activities was $7,149,000 for Q1 2025, compared to $6,653,000 for Q1 2024, indicating a 7% increase in cash outflow[23] Research and Development - Research and Development (R&D) expenses increased to $5.7 million in Q1 2025 from $3.7 million in Q1 2024, primarily due to the continuation of the ReMEDy2 clinical trial and global expansion[8] - Research and development expenses increased to $5,656,000 in Q1 2025 from $3,676,000 in Q1 2024, reflecting a 54% increase[19] - Enrollment in the Phase 2/3 ReMEDy2 trial for acute ischemic stroke is progressing as planned, with an interim analysis on the first 200 patients expected in the first half of 2026[5] - The Phase 2 trial for DM199 in preeclampsia will enroll up to 90 women with preeclampsia and 30 women with fetal growth restriction[10] Administrative Expenses - General and Administrative (G&A) expenses rose to $2.5 million in Q1 2025 from $2.1 million in Q1 2024, mainly due to additional non-cash share-based compensation[8] Assets and Liabilities - Total current assets decreased to $37,422,000 as of March 31, 2025, down from $44,610,000 as of March 31, 2024, a decline of 16%[21] - Total assets decreased to $38,830,000 as of March 31, 2025, compared to $46,345,000 as of December 31, 2024, a decrease of 16%[21] - Total liabilities decreased to $4,876,000 as of March 31, 2025, down from $5,627,000 as of December 31, 2024, a decrease of 13%[21] Upcoming Events - A virtual key opinion leader (KOL) event is scheduled for May 28, 2025, to discuss the treatment landscape for preeclampsia and the DM199 Phase 2 study design[4] Clinical Study Results - Topline safety and efficacy results from Part 1A of the Phase 2 preeclampsia study are expected between the second half of June and the first half of July 2025[2]